Cargando…
Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266683/ https://www.ncbi.nlm.nih.gov/pubmed/25506699 http://dx.doi.org/10.1371/journal.pone.0115250 |
_version_ | 1782349048452218880 |
---|---|
author | Estañ, María Cristina Calviño, Eva Calvo, Susana Guillén-Guío, Beatriz Boyano-Adánez, María del Carmen de Blas, Elena Rial, Eduardo Aller, Patricio |
author_facet | Estañ, María Cristina Calviño, Eva Calvo, Susana Guillén-Guío, Beatriz Boyano-Adánez, María del Carmen de Blas, Elena Rial, Eduardo Aller, Patricio |
author_sort | Estañ, María Cristina |
collection | PubMed |
description | Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells. Etomoxir caused negligible lethality at concentrations up to 100 µM, but efficaciously cooperated to cause apoptosis with the anti-leukemic agent arsenic trioxide (ATO, Trisenox), and with lower efficacy with other anti-tumour drugs (etoposide, cisplatin), in HL60 cells. Etomoxir-ATO cooperation was also observed in NB4 human acute promyelocytic cells, but not in normal (non-tumour) mitogen-stimulated human peripheral blood lymphocytes. Biochemical determinations in HL60 cells indicated that etomoxir (25–200 µM) dose-dependently inhibited mitochondrial respiration while slightly stimulating glycolysis, and only caused marginal alterations in total ATP content and adenine nucleotide pool distribution. In addition, etomoxir caused oxidative stress (increase in intracellular reactive oxygen species accumulation, decrease in reduced glutathione content), as well as pro-apoptotic LKB-1/AMPK pathway activation, all of which may in part explain the chemo-sensitizing capacity of the drug. Etomoxir also cooperated with glycolytic inhibitors (2-deoxy-D-glucose, lonidamine) to induce apoptosis in HL60 cells, but not in NB4 cells. The combined etomoxir plus 2-deoxy-D-glucose treatment did not increase oxidative stress, caused moderate decrease in net ATP content, increased the AMP/ATP ratio with concomitant drop in energy charge, and caused defensive Akt and ERK kinase activation. Apoptosis generation by etomoxir plus 2-deoxy-D-glucose was further increased by co-incubation with ATO, which is apparently explained by the capacity of ATO to attenuate Akt and ERK activation. In summary, co-treatment with etomoxir may represent an interesting strategy to increase the apoptotic efficacy of ATO and (with some limitations) 2-deoxy-D-glucose which, although clinically important anti-tumour agents, exhibit low efficacy in monotherapy. |
format | Online Article Text |
id | pubmed-4266683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42666832014-12-26 Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities Estañ, María Cristina Calviño, Eva Calvo, Susana Guillén-Guío, Beatriz Boyano-Adánez, María del Carmen de Blas, Elena Rial, Eduardo Aller, Patricio PLoS One Research Article Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells. Etomoxir caused negligible lethality at concentrations up to 100 µM, but efficaciously cooperated to cause apoptosis with the anti-leukemic agent arsenic trioxide (ATO, Trisenox), and with lower efficacy with other anti-tumour drugs (etoposide, cisplatin), in HL60 cells. Etomoxir-ATO cooperation was also observed in NB4 human acute promyelocytic cells, but not in normal (non-tumour) mitogen-stimulated human peripheral blood lymphocytes. Biochemical determinations in HL60 cells indicated that etomoxir (25–200 µM) dose-dependently inhibited mitochondrial respiration while slightly stimulating glycolysis, and only caused marginal alterations in total ATP content and adenine nucleotide pool distribution. In addition, etomoxir caused oxidative stress (increase in intracellular reactive oxygen species accumulation, decrease in reduced glutathione content), as well as pro-apoptotic LKB-1/AMPK pathway activation, all of which may in part explain the chemo-sensitizing capacity of the drug. Etomoxir also cooperated with glycolytic inhibitors (2-deoxy-D-glucose, lonidamine) to induce apoptosis in HL60 cells, but not in NB4 cells. The combined etomoxir plus 2-deoxy-D-glucose treatment did not increase oxidative stress, caused moderate decrease in net ATP content, increased the AMP/ATP ratio with concomitant drop in energy charge, and caused defensive Akt and ERK kinase activation. Apoptosis generation by etomoxir plus 2-deoxy-D-glucose was further increased by co-incubation with ATO, which is apparently explained by the capacity of ATO to attenuate Akt and ERK activation. In summary, co-treatment with etomoxir may represent an interesting strategy to increase the apoptotic efficacy of ATO and (with some limitations) 2-deoxy-D-glucose which, although clinically important anti-tumour agents, exhibit low efficacy in monotherapy. Public Library of Science 2014-12-15 /pmc/articles/PMC4266683/ /pubmed/25506699 http://dx.doi.org/10.1371/journal.pone.0115250 Text en © 2014 Estañ et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Estañ, María Cristina Calviño, Eva Calvo, Susana Guillén-Guío, Beatriz Boyano-Adánez, María del Carmen de Blas, Elena Rial, Eduardo Aller, Patricio Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities |
title | Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities |
title_full | Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities |
title_fullStr | Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities |
title_full_unstemmed | Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities |
title_short | Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities |
title_sort | apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266683/ https://www.ncbi.nlm.nih.gov/pubmed/25506699 http://dx.doi.org/10.1371/journal.pone.0115250 |
work_keys_str_mv | AT estanmariacristina apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT calvinoeva apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT calvosusana apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT guillenguiobeatriz apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT boyanoadanezmariadelcarmen apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT deblaselena apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT rialeduardo apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities AT allerpatricio apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities |